Literature DB >> 307560

Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

H R Gralnick.   

Abstract

The normal Factor VIII/von Willebrand factor protein has the ability to agglutinate or aggregate normal platelets in the presence of ristocetin (von Willebrand factor activity). Removal of greater than 95% of the sialic acid from this protein by neuraminidase did not affect the von Willebrand factor or procoagulant activity. However, oxidation of the penultimate galactose of the asialo Factor VIII/von Willebrand factor protein with galactose oxidase resulted in a progressive loss of von Willebrand factor activity with no effect on procoagulant activity. Reduction of the 6-aldehydo intermediate by potassium borohydride caused full regeneration of von Willebrand factor activity. These studies confirm the identification of the intact penultimate galactose moiety as a critical determinant of von Willebrand factor activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 307560      PMCID: PMC371789          DOI: 10.1172/JCI109152

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein.

Authors:  J M Sodetz; S V Pizzo; P A McKee
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

4.  The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH.

Authors:  B S Coller; B R Franza; H R Gralnick
Journal:  Blood       Date:  1976-05       Impact factor: 22.113

5.  Dissociation between human platelet agglomerating activity and factor VIII procoagulant activity of bovine plasma preparations by chemical treatment. I. Effect of neuraminidase.

Authors:  S Levy-Toledano; J P Caen; T Halmos; L Mester
Journal:  Pathol Biol (Paris)       Date:  1973-11

6.  Purification of neuraminidases from Vibrio Cholerae, Clostridium Perfringens and influenza virus by affinity chromatography.

Authors:  P Cuatrecasas; G Illiano
Journal:  Biochem Biophys Res Commun       Date:  1971-07-02       Impact factor: 3.575

7.  Factor VIII-associated platelet aggregation.

Authors:  E P Kirby
Journal:  Thromb Haemost       Date:  1977-12-15       Impact factor: 5.249

8.  Von Willebrand's disease: combined qualitative and quantitative abnormalities.

Authors:  H R Gralnick; Y Sultan; B S Coller
Journal:  N Engl J Med       Date:  1977-05-05       Impact factor: 91.245

9.  Abnormal factor VIII related antigen (FVIIIRAG) in von Willebrand's disease (vWd): decreased precipitation by concanavalin A.

Authors:  I R Peake; A L Bloom
Journal:  Thromb Haemost       Date:  1977-04-30       Impact factor: 5.249

10.  Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease.

Authors:  H R Gralnick; B S Coller; Y Sultan
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

View more
  9 in total

1.  Production and Purification of Rabbit's Polyclonal Antibody Against Factor VIII.

Authors:  Simin Sohrabi; Azim Akbarzadeh; Dariush Norouzian; Ali Farhangi; Mehri Mortazavi; Mohammad Reza Mehrabi; Mohsen Chiani; Zahra Saffari; Soheil Ghassemi
Journal:  Indian J Clin Biochem       Date:  2011-06-08

2.  Von Willebrand's disease: a clinical and molecular enigma. Twelfth Annual Paul M. Aggeler Memorial Lecture.

Authors:  R L Nachman
Journal:  West J Med       Date:  1982-04

3.  Carbohydrate of the factor VIII/von Willebrand factor in von Willebrand's disease.

Authors:  T S Zimmerman; R Voss; T S Edgington
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

4.  Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

Authors:  A B Federici; J H Elder; L De Marco; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

5.  A fibronectin-binding glycoprotein from human platelet membranes.

Authors:  M S Hansen; I Clemmensen
Journal:  Biochem J       Date:  1982-03-01       Impact factor: 3.857

6.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

Authors:  L De Marco; S S Shapiro
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

7.  Role of carbohydrate in multimeric structure of factor VIII/von Willebrand factor protein.

Authors:  H R Gralnick; S B Williams; M E Rick
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

8.  Desialylation of O-glycans activates von Willebrand factor by destabilizing its autoinhibitory module.

Authors:  Kayleigh M Voos; Wenpeng Cao; Nicholas A Arce; Emily R Legan; Yingchun Wang; Asif Shajahan; Parastoo Azadi; Pete Lollar; Xiaohui Frank Zhang; Renhao Li
Journal:  J Thromb Haemost       Date:  2021-09-26       Impact factor: 16.036

9.  The role of neuraminidase 1 and 2 in glycoprotein Ibα-mediated integrin αIIbβ3 activation.

Authors:  Dianne E van der Wal; April M Davis; Melanie Mach; Denese C Marks
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.